A protein vaccine designed to target all four variations of the dengue virus proves effective in mouse trials

September 11, 2015, Agency for Science, Technology and Research (A*STAR), Singapore
A protein vaccine designed to target all four variations of the dengue virus proves effective in mouse trials
Dengue fever, spread by mosquitoes, has proven difficult to immunize against, but a new vaccine being tested at A*STAR shows great promise. Credit: Noppharat05081977/iStock/Thinkstock

A breakthrough in the search for safe immunization against dengue fever has emerged after trials at A*STAR showed a new vaccine without live viruses induces an effective immune response.

Dengue fever is a debilitating tropical disease spread by mosquitoes, against which a global research effort has failed to develop a universally approved vaccine. Crucially, the comes in four variations, known as serotypes, and for a vaccine to be effective it must target all four serotypes at once. Cuban scientists developed a new potential vaccine and sought input from Katja Fink and colleagues at the A*STAR Singapore Immunology Network (SIgN).

"Several vaccine candidates have been developed, but they all have shortcomings," says Fink. "Vaccines that contain live viruses can produce a strong immune response, but cause unwanted side effects. From a safety point of view it is preferable to have protein-only approaches."

One promising candidate is the dengue virus E protein, which includes epitopes—protein regions that are recognized and targeted by the —found on all four dengue serotypes. A specific part of the E protein, called DIII, is targeted by particularly potent neutralizing antibodies. However, DIII tends to attract only one type of lymphocyte, called B . B cells are good for neutralizing viruses on repeated infection, but a strong response also requires T cells to kill infected cells, to support the B cells and establish immune memory.

Researchers at the Center for Genetic Engineering and Biotechnology in Havana combined DIII with the capsid protein (C) found on all four serotypes, which has effective T-cell epitopes, to produce an aggregate vaccine named DIIIC and asked Fink's group to analyze exactly what sort of it would induce.

Extended trials on immunized mice revealed that the DIIIC vaccine induced a so-called Th1-type response, which helps to promote cytotoxic T cells and regulate the production of antibodies from B cells. Moreover, the antibodies induced by DIIIC were still at useful levels 120 days after immunization.

"In natural dengue infection an imbalance towards a Th2 response appears to be associated with more severe disease and a stronger Th1 response is preferred, so it is encouraging to see an efficient, long-lasting Th1 response to DIIIC," says Fink. Her team hopes to continue collaboration with their Cuban counterparts to understand and develop this promising for clinical trials using A*STAR's state-of-the-art facilities.

Explore further: Scientists identify the skin immune cells targeted by the dengue virus

More information: "Tetravalent dengue DIIIC protein together with alum and ODN elicits a Th1 response and neutralizing antibodies in mice." Vaccine 33, 1474–1482 (2015). dx.doi.org/10.1016/j.vaccine.2015.01.074

Related Stories

Scientists identify the skin immune cells targeted by the dengue virus

June 24, 2015
Cells in the skin immune system that act as 'gateways' enabling the dengue virus to spread through the body have been identified by A*STAR researchers.

Targeting key cells for a dengue virus infection model

November 5, 2014
Dengue virus infects hundreds of millions of people living in tropical countries every year. Transmitted via mosquito bites, the virus typically causes fever, but may also lead to potentially fatal organ failure. The development ...

Study finds viral protein that causes dengue shock

September 9, 2015
Scientists at the University of California, Berkeley, have identified a key culprit responsible for the fluid loss and resulting shock that are the hallmark of severe - and potentially fatal - dengue virus infections.

New strategy to disarm the dengue virus brings new hope for a universal dengue vaccine

August 13, 2013
A new strategy that cripples the ability of the dengue virus to escape the host immune system has been discovered by A*STAR's Singapore Immunology Network (SIgN). This breakthrough strategy opens a door of hope to what may ...

Insights obtained by profiling immune response to repeat viral infections could assist vaccine design efforts

March 27, 2013
Patients who successfully beat infection with dengue virus remain vulnerable to reinfection by other dengue variants, and these secondary infections tend to be more severe. The antibodies arising from the immune system's ...

Epstein-Barr virus vaccine elicits potent neutralizing antibodies in animals

August 13, 2015
Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and their collaborators have developed an experimental, nanoparticle-based vaccine against Epstein-Barr ...

Recommended for you

Anticancer drug offers potential alternative to transplant for patients with liver failure

August 15, 2018
Patients suffering sudden liver failure could in the future benefit from a new treatment that could reduce the need for transplants, research published today shows.

Study shows how MERS coronavirus evolves to infect different species

August 14, 2018
In the past 15 years, two outbreaks of severe respiratory disease were caused by coronaviruses transmitted from animals to humans. In 2003, SARS-CoV (severe acute respiratory syndrome coronavirus) spread from civets to infect ...

Inching closer to a soft spot in isoniazid-resistant tuberculosis

August 14, 2018
Antibiotic-resistant tuberculosis is a public health threat. TB and other bacteria become resistant to antibiotics by evolving genetic changes over time, which they can do quite quickly because bacterial lifecycles are short. ...

Why do women get more migraines?

August 14, 2018
Research published today reveals a potential mechanism for migraine causation which could explain why women get more migraines than men. The study, in Frontiers in Molecular Biosciences, suggests that sex hormones affect ...

How long is an Ebola survivor contagious? One case is causing scientists to rethink the answer.

August 14, 2018
Surviving Ebola isn't like getting over the flu.

Link between common 'harmless' virus and cardiovascular damage

August 13, 2018
Researchers from Brighton and Sussex Medical School (BSMS) have found an unexpectedly close link between a herpes virus and the occurrence of immune cells damaging cardiovascular tissue.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.